Wells Fargo Maintains Overweight on Versigent, Raises Price Target to $42
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Colin Langan maintains Versigent (NYSE:VGNT) with a Overweight and raises the price target from $35 to $42.
Wells Fargo analyst Colin Langan maintains Versigent (NYSE:VGNT) with a Overweight and raises the price target from $35 to $42.